Last Updated: 2:18am BST 18/04/2008
By Jonathan Russell
UK BIOTECH firm Intercytex is to get a share of an $85m (£42.8m) US military grant to develop regenerative treatment for wounded soldiers.
Washington is expected to announce today that it is pouring millions of dollars into finding ways of rebuilding body parts and organs. Intercytex will get a share of the funding to advance its regenerative skin graft technology.
Nick Higgins, chief executive of Intercytex, said: "Regenerative medicine, the restoration and repair of human tissues and organs, has the potential to revolutionise the treatment of patients.
“As the only UK representative, we are immensely proud to be involved in this key initiative launched by the US government, and we are confident that we can make a significant contribution.”
Intercytex’s contribution will be directed at treating extensive burns and loss of skin suffered on the battlefield. However, it is understood the technology could also be used to treat trauma and burns in the general public.
The company will use technology aimed at getting laboratory-made living human skin to be integrated into the human body. The company claims its technology differs from other skin graft alternatives which biodegrade in a few weeks, too rapidly to act as skin grafts, says the company.
Intercytex is also developing hair and facial skin regeneration products derived from unmodified human cells. The products are designed to treat facial scarring through acne and male pattern baldness.
The company is the only British one in the newly formed US Armed Forces Institute of Regenerative Medicines.